Company intelligence / Profile preview

EirGenix

Ownership: Private
Employees: ~1000
Development stage: Commercial

Overview

EirGenix has successfully completed Phase III clinical trials for its trastuzumab biosimilar EG12014, demonstrating bioequivalence to Roche’s Herceptin®. The company has submitted a BLA to the US FDA and is in the regulatory filing stage. Other pipeline programs are at earlier stages ranging from preclinical to Phase 1.

Therapeutic areas: Oncology
Modalities: Monoclonal antibodies (mAbs)Bi-specific mAbsRecombinant proteinsAntibody-drug conjugates (ADCs)Fusion proteinsRNA-based therapeuticsViral vectors
Industry: Biotech

Drug pipeline

2 assets

trastuzumab biosimilar EG12014

1 more asset in the full pipeline.

Request access →

Partnerships

Sandoz – global licensing collaboration for Trastuzumab biosimilar (EG12014)Bolt Biotherapeutics – customer relationship

Beyond the preview

Go deeper on EirGenix.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EirGenix.

Explore the full profile